SG Americas Securities
OVID icon

SG Americas Securities’s Ovid Therapeutics OVID Stock Holding History

SG Americas Securities’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Buy
+13,613
New +$35.1K ﹤0.01% 3230
2025
Q2 		– Sell
-43,028
Closed -$13K – 3418
2025
Q1 		$13K Buy
43,028
+5,392
+14% +$3.32K ﹤0.01% 3401
2024
Q4 		$35K Buy
37,636
+17,172
+84% +$19.2K ﹤0.01% 2967
2024
Q3 		$24K Buy
+20,464
New +$21.4K ﹤0.01% 3335
2024
Q2 		– Sell
-35,938
Closed -$110K – 3190
2024
Q1 		$110K Sell
35,938
-3,854
-10% -$12.9K ﹤0.01% 2484
2023
Q4 		$128K Buy
39,792
+13,728
+53% +$46.9K ﹤0.01% 2550
2023
Q3 		$100K Buy
+26,064
New +$93.7K ﹤0.01% 2794
2020
Q3 		– Sell
-23,422
Closed -$173K – 3249
2020
Q2 		$173K Buy
+23,422
New +$110K ﹤0.01% 2969
2019
Q1 		– Sell
-18,870
Closed -$46K – 3545
2018
Q4 		$46K Buy
+18,870
New +$86.1K ﹤0.01% 2833

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SG Americas Securities's OVID Position: Q2 2026 in Review

SG Americas Securities opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 13,613 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #3230 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in OVID as recently as Q1 2025.

SG Americas Securities first reported a position in OVID in Q4 2018 and has held it in 9 quarters since. The position peaked at $173K in Q2 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • SG Americas Securities held 13,613 shares of Ovid Therapeutics worth $37K as of Q2 2026.
  • Ovid Therapeutics was a new SG Americas Securities position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3230 holding.
  • SG Americas Securities first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 9 quarters since.
  • SG Americas Securities's Ovid Therapeutics position peaked at $173K in Q2 2020.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.